natgillin/translations-raw huggingface dataset:
Prevenar will not protect against other Streptococcus pneumoniae serotypes than those included in the vaccine or other micro-organisms that cause invasive disease or otitis media.
Cepivo Prevenar ne ščiti proti drugim serotipom Streptococcus pneumoniae, razen proti tistim, ki jih vsebuje, in tudi ne prepreči okužbe z drugimi mikroorganizmi, ki povzročajo invazivne okužbe ali vnetje srednjega ušesa.
prevent blood clots in the brain (stroke) and other blood vessels in the body if you have a form of irregular heart rhythm called nonvalvular atrial fibrillation and at least one additional risk factor.
za preprečevanje nastanka krvnih strdkov v možganih (možganska kap) in drugih krvnih žilah telesa, če imajo obliko nerednega srčnega ritma, ki se imenuje nevalvularna atrijska fibrilacija, in vsaj še en dodaten dejavnik tveganja.
prevent the formation of blood clots during and shortly after a period of restricted mobility due
preprečevanje nastajanja krvnih strdkov med obdobjem in po obdobju omejene gibljivosti
prevent the formation of blood clots in the blood vessels of the legs or lungs after orthopaedic surgery (such as hip or knee surgery) or abdominal surgery
preprečevanje tvorbe krvnih strdkov v žilah nog ali pljuč po ortopedskih operacijah (kot so operacije kolka ali kolen) ali po operacijah v trebušni votlini.
prevent the formation of blood clots in the blood vessels of the legs or lungs after orthopaedic surgery (such as hip or knee surgery) or abdominal surgery
preprečevanje tvorbe krvnih strdkov v žilah nog ali pljuč po ortopedskih operacijah (kot so operacije kolka ali kolen) ali po operacijah v trebušni votlini;
Preventing recurrence in bipolar disorder:
Preprečevanje ponovnega pojava bolezni pri bipolarni motnji:
preventing rejection of transplanted organs (ciclosporin).
preprečevanju zavrnitve presajenih organov (npr. ciklosporin),
Prevention (LEVP 2006-4): Prior to enrollment, 23 children (age range: 3 to 17 years) reported a median monthly HAE attack rate of 3.0 (range: 0.5-28.0).
Preprečevanje (LEVP 2006-4): Pred vključitvijo v študijo je 23 otrok (razpon starosti: 3 do 17 let) poročalo o mediani mesečni pogostnosti napadov HAE 3,0 (razpon: 0,5-28,0).
Prevention and treatment of postoperative pain and inflammation associated with cataract surgery.
Preprečevanje in zdravljenje pooperativne bolečine in vnetja, povezanih z operacijo katarakte.
Prevention during an influenza epidemic has not been studied in children below 12 years of age.
Preprečevanje gripe med epidemijo v okolici ni bilo preučevano pri otrocih, mlajših od 12 let.
Prevention during an influenza epidemic in the community
Preprečevanje gripe med epidemijo v okolici
Prevention during an influenza epidemic in the community: In a pooled analysis of two other studies conducted in unvaccinated otherwise healthy adults, oseltamivir 75 mg once daily given for 6 weeks significantly reduced the incidence of clinical influenza illness from 25 /519 (4.8 %) in the placebo group to 6/520 (1.2 %) in the oseltamivir group (76 % reduction [95 % CI 1.6 – 5.7; p = 0.0006]) during a community outbreak of influenza.
Preprečevanje gripe med epidemijo v okolici: skupna analiza dveh drugih študij, ki so ju opravili pri necepljenih, sicer zdravih odraslih, ki so prejemali 75 mg oseltamivirja enkrat na dan 6 tednov, je pokazala pomembno zmanjšanje pogostnosti klinične oblike gripe v skupini, ki je jemala oseltamivir med izbruhom gripe v okolici (6/520 (1,2 %)) v primerjavi s placebo skupino (25/519, (4,8 %)) (76 % zmanjšanje [95-% interval zaupanja 1,6 – 5,7; p = 0,0006]).
Prevention during an influenza epidemic in the community: In a pooled analysis of two other studies conducted in unvaccinated otherwise healthy adults, oseltamivir 75 mg once daily given for 6 weeks significantly reduced the incidence of clinical influenza illness from 25/519 (4.8 %) in the placebo group to 6/520 (1.2 %) in the oseltamivir group (76 % reduction [95 % CI 1.6 – 5.7; p = 0.0006]) during a community outbreak of influenza.
Preprečevanje gripe med epidemijo v okolici: skupna analiza dveh drugih študij, ki so ju opravili pri necepljenih, sicer zdravih odraslih, ki so prejemali 75 mg oseltamivirja enkrat na dan 6 tednov, je pokazala pomembno zmanjšanje pogostnosti klinične oblike gripe v skupini, ki je jemala oseltamivir med izbruhom gripe v okolici (6/520 (1,2 %)) v primerjavi s placebo skupino (25/519, (4,8 %)) (76 % zmanjšanje 95-% interval zaupanja 1,6–5,7; p = 0,0006).
Prevention during an influenza epidemic in the community: Prevention during an influenza epidemic has not been studied in children below 12 years of age.
Preprečevanje gripe med epidemijo v okolici: preprečevanje gripe med epidemijo v okolici ni bilo preučevano pri otrocih, mlajših od 12 let.
Prevention of
Preprečevanje
prevention of
Preprečevanje in zdravljenje
Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy in adults.
Preprečevanje akutne in zapoznele navzee in bruhanja, povezanih z zelo emetogeno kemoterapijo rakavih bolezni na osnovi cisplatina, pri odraslih.
Prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures
za preprečevanje akutnega izgubljanja kostnine zaradi nenadne nepokretnosti, na primer pri bolnikih z nedavnim osteoporoznim zlomom;
Prevention of anaemia of prematurity in infants with a birth weight of 750 to 1500 g and a gestational age of less than 34 weeks.
Preprečevanje anemije pri nedonošenčkih s porodno maso 750 do 1500 g in manjšo gestacijsko starostjo od 34 tednov.
Prevention of anthracycline cardiotoxicity, and
Preprečevanje kardiotoksičnosti antraciklina in
Prevention of atherothrombotic events
Preprečevanje aterotrombotičnih dogodko
Prevention of atherothrombotic events
Preprečevanje aterotrombotičnih dogodkov:
Prevention of atherothrombotic events in patients after an ACS
Preprečevanje aterotrombotičnih dogodkov pri bolnikih po akutnem koronarnem sindromu
Prevention of blood clot formation after knee or hip replacement surgery
Preprečevanje nastajanja krvnih strdkov po operativni vstavitvi umetnega kolena ali kolka
Prevention of blood clot formation after knee or hip replacement surgery
Preprečitev nastajanja krvnih strdkov po operativni vstavitvi umetnega kolena ali kolka
Prevention of brain or body vessel obstruction by blood clot formation developing after abnormal heart beats and Treatment of blood clots in the veins of your legs and lungs including prevention of blood clots from re-occuring in the vein of your legs and lungs
Preprečevanje zapore krvnih žil v možganih ali telesu s krvnimi strdki, ki se razvijejo pri motnjah srčnega utripa, in zdravljenje krvnih strdkov v venah nog in pljučih ter preprečevanje njihove ponovitve
Prevention of Chemotherapy Induced Nausea and Vomiting (CINV):
Preprečevanje s kemoterapijo povzročene navzee in bruhanja (Chemotherapy Induced Nausea and
Prevention of Chemotherapy Induced Nausea and Vomiting (CINV):
Preprečevanje s kemoterapijo povzročene navzee in bruhanja (Chemotherapy Induced Nausea and Vomiting – CINV):
Prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.
Preprečevanje globoke venske tromboze pri bolnikih z elektivno operacijo za zamenjavo kolka ali kolena.
Prevention of environmental flea contamination by inhibiting the development of flea immature stages (eggs, larvae and pupae) for over a month.
Preprečevanje kontaminacije okolice z bolhami s preprečevanjem razvoja nezrelih razvojnih oblik bolh (jajčec, ličink in bub) več kot 1 mesec.
Prevention of environmental flea contamination by inhibiting the development of flea immature stages (eggs, larvae and pupae) for over a month.
Preprečevanje kontaminacije okolice z bolhami z inhibicijo razvoja nezrelih razvojnih oblik bolh (jajčec, ličink in bub) več kot 1 mesec.
Prevention of extracorporeal thrombus formation during haemodialysis
Preprečevanje nastanka krvnih strdkov v zunajtelesnem krvnem obtoku med hemodializo
Prevention of fungal infections in high risk bone marrow transplant recipients
Preprečevanje glivičnih okužb pri prejemnikih presadka kostnega mozga, pri katerih obstaja veliko tveganje.
Prevention of gonadal function in bitches via long term blockade of gonadotrophin synthesis.
Preprečevanje gonadne funkcije pri psicah z dolgotrajno blokado sinteze gonadotropina
Prevention of haemorrhage in case of surgery
Preprečevanje krvavitev v primeru kirurškega posega
Prevention of heartworm disease (cats and dogs)
Preprečevanje obolenja pri okužbi z Dirofilario immitis (mačke in psi)
Prevention of heartworm disease (cats and dogs)
Preprečevanje obolenja pri okužbi z Dirofilario immitis (psi in mačke)
Prevention of heartworm disease (D. immitis) and cutaneous dirofilariosis (skin worm) (D. repens)
Preprečevanje infestacije s srčno glisto (Dirofilario immitis) in kožno obliko dirofilarioze, ki jo povzroča D.repens (kožna glista)
Prevention of heartworm disease (D. immitis) and cutaneous dirofilariosis (skinworm) (D. repens)
Preprečevanje infestacije s srčno glisto (Dirofilario immitis) in kožno obliko dirofilarioze (kožna glista), ki jo povzroča D.repens
Prevention of heartworm disease (Dirofilaria immitis larvae) for one month.
Preprečevanje razvoja srčne gliste (Dirofilaria immitis ličinke) 1 mesec.
Prevention of heartworm disease (Dirofilaria immitis larvae) with monthly administration.
Preprečevanje razvoja srčne gliste (Dirofilaria immitis ličinke) 1-krat mesečno dajanje zdravila .
Prevention of hepatitis B in case of accidental exposure in non-immunised subjects
Preprečevanje hepatitisa B v primeru nenamerne izpostavitve necepljene osebe
Prevention of hepatitis B in case of accidental exposure in non-immunised subjects:
Preprečevanje hepatitisa B v primeru nenamerne izpostavitve necepljene osebe:
Prevention of hepatitis B in the newborn, of a hepatitis B virus carrier-mother, at birth or as soon as possible after birth:
Preprečevanje hepatitisa B pri novorojencu, rojenemu prenašalki virusa hepatitisa B, ob rojstvu ali v najkrajšem možnem času po rojstvu:
Prevention of hepatitis B in the newborn, of a hepatitis B virus carrier-mother, at birth or as soon as possible after birth:
Preprečevanje hepatitisa B pri novorojencu, rojenemu prenašalki virusa hepatitisa B, ob rojstvu ali čim prej po rojstvu:
Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure.
Preprečevanje ponovne okužbe z virusom hepatitisa tipa B (HBV) pri HBsAg- in HBV–DNK negativnih odraslih bolnikih vsaj en teden po presaditvi jeter zaradi s hepatitisom tipa B izzvane odpovedi jeter.
Prevention of HZ cases with severe pain in the entire SPS study population
Preprečevanje primerov herpesa zostra s hudo bolečino v celotni populaciji študije SPS
Prevention of medical errors and injection/infusion reactions
preprečevanje medicinskih napak in reakcij, povezanih z injiciranjem/infundiranjem,
Prevention of motion sickness only
Preprečevanje slabosti zaradi vožnje
Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
Preprečevanje navzee in bruhanja, povezanih z zmerno emetogeno kemoterapijo rakavih bolezni, pri odraslih.
Prevention of nausea induced by chemotherapy Treatment and prevention of vomiting (except motion sickness)
Preprečevanje slabosti povzročene s kemoterapijo Zdravljenje ter preprečevanje bruhanja (razen slabosti zaradi vožnje)
Prevention of nausea induced by chemotherapy Treatment and prevention of vomiting (except motion sickness)
Preprečevanje slabosti povzročene zaradi kemoterapije Zdravljenje ter preprečevanje bruhanja (razen slabosti zaradi vožnje)
prevention of organ transplant rejection
preprečevanje zavrnitve presajenega organa
Prevention of ovulation1,§
Preprečitev ovulacije1,§
Prevention of photosensitivity reactions
Preprečevanje fotosenzibilizacijskih reakcij
Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques.
Preprečevanje prezgodnje ovulacije pri bolnicah v postopku nadzorovane ovarijske stimulacije, ki ji sledi vsrkanje oocitov in tehnike asistirane reprodukcije.
Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases
preprečevanje z okostjem povezanih dogodkov (patološke frakture, zapleti, pri katerih je potrebno obsevanje ali kirurški poseg) pri bolnikih z rakom dojke in metastazami v kosteh;
Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases
preprečevanje z okostjem povezanih dogodkov (patološke frakture; zapleti, pri katerih je potrebno obsevanje ali kirurški poseg) pri bolnikih z rakom dojke in metastazami v kosteh;
Prevention of skeletal events in patients with breast cancer and bone metastases with Bondronat 6 mg administered intravenously was assessed in one randomized placebo controlled phase III trial with a duration of 96 weeks.
Preprečevanje z okostjem povezanih dogodkov pri bolnikih z rakom dojke in metastazami v kosteh z zdravilom Bondronat 6 mg, danim intravensko, so raziskovali v randomiziranem s placebom kontroliranim preskušanju faze III, ki je potekala 96 tednov.
Prevention of skeletal events in patients with breast cancer and bone metastases with Ibandronate 6 mg administered intravenously was assessed in one randomized placebo controlled phase III trial with duration of 96 weeks.
Preprečevanje z okostjem povezanih dogodkov pri bolnikih z rakom dojke in metastazami v kosteh z ibandronsko kislino (6 mg), dano intravensko, so raziskovali v randomiziranem s placebom kontroliranem preskušanju faze III, ki je potekala 96 tednov.
Prevention of skeletal events in patients with breast cancer and bone metastases with Ibandronate6 mg administered intravenously was assessed in one randomized placebo controlled phase III trial with duration of 96 weeks.
Preprečevanje z okostjem povezanih dogodkov pri bolnikih z rakom dojke in metastazami v kosteh z ibandronsko kislino (6 mg), dano intravensko, so raziskovali v randomiziranem s placebom kontroliranem preskušanju faze III, ki je potekala 96 tednov.
Prevention of skeletal events in patients with breast cancer and bone metastases with ibandronic acid 50 mg tablets was assessed in two randomized placebo controlled phase III trials with a duration of 96 weeks.
Preprečevanje z okostjem povezanih dogodkov pri bolnikih z rakom dojke in metastazami v kosteh s 50 mg tabletami ibandronske kisline so raziskovali v dveh randomiziranih, s placebom nadzorovanih preskušanjih faze III, ki so potekala 96 tednov.
Prevention of skeletal events in patients with breast cancer and bone metastases with ibandronic acid 6 mg administered intravenously was assessed in one randomized placebo controlled phase III trial with a duration of 96 weeks.
Preprečevanje z okostjem povezanih dogodkov pri bolnikih z rakom dojke in metastazami v kosteh z ibandronsko kislino 6 mg, dano intravensko, so raziskovali v randomiziranem s placebom kontroliranem preskušanju faze III, ki je potekala 96 tednov.
Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.
Preprečevanje skeletnih dogodkov (patoloških zlomov, obsevanja kosti, kompresije hrbtenjače ali operacije kosti) pri odraslih s kostnimi metastazami solidnih tumorjev.
Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.
Preprečevanje z okostjem povezanih dogodkov (patološki zlomi, spinalna kompresija, obsevanje ali operacija kosti ali tumorsko povzročena hiperkalciemija) pri odraslih bolnikih z napredovalimi malignimi boleznimi, ki zajamejo kosti.
Prevention of stroke and SEE in adult patients with nonvalvular atrial fibrillation with one or more risk factors (SPAF)
Preprečevanje možganske kapi in sistemske embolije pri odraslih bolnikih z nevalvularno atrijsko fibrilacijo in enim ali več dejavniki tveganja (SPAF)
Prevention of stroke and SEE in adult patients with nonvalvular atrial fibrillation with one or more risk factors (SPAF)
Preprečevanje možganske kapi in sistemske embolije pri odraslih bolnikih z nevalvularno atrijsko fibrilacijo z enim ali več dejavniki tveganja (SPAF)
Prevention of stroke and SEE in adult patients with NVAF with one or more risk factors
Preprečevanje možganske kapi in sistemskih emboličnih dogodkov pri odraslih bolnikih z NVAF in enim ali več dejavniki tveganja
Prevention of stroke and SEE in adult patients with NVAF with one or more risk factors
Preventiva možganske kapi in sistemskega emboličnega dogodka pri odraslih z NVAF z enim ali več dejavniki tveganja
Prevention of stroke and SEE in adult patients with NVAF with one or more risk factors (SPAF)
Preprečevanje možganske kapi in sistemskih emboličnih dogodkov pri bolnikih z NVAF in enim ali več dejavniki tveganja (SPAF)
Prevention of stroke and systemic embolism
Preprečevanje možganske kapi in sistemskih embolij
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).
Preprečevanje možganske kapi in sistemske embolije pri odraslih bolnikih z nevalvularno atrijsko fibrilacijo (NVAF - Non-Valvular Atrial Fibrillation) in enim ali več dejavniki tveganja, kot so predhodna možganska kap ali prehodna možganska ishemija (TIA - Transient Ischaemic Attack); starost ≥ 75 let; hipertenzija; sladkorna bolezen; simptomatsko srčno popuščanje (razred ≥ II po NYHA).
Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
Preprečevanje možganske kapi in sistemske embolije pri bolnikih z nevalvularno atrijsko fibrilacijo
Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF)
Preprečevanje možganske kapi in sistemske embolije pri bolnikih z nevalvularno atrijsko fibrilacijo (NVAF)
Prevention of stroke and systemic embolism: NVAF
Preprečevanje možganske kapi in sistemske embolije: NVAF
Prevention of surgical site infections in adults following surgery of the colon or rectum.
Preventiva: preventiva pred okužbami na mestu posega v debelem črevesju ali danki pri odraslih.
Prevention of swelling attacks
Preprečevanje napadov otekanja
Prevention of Venous Thromboembolic Events (VTE) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery (see section 5.1).
Preprečevanje venskih trombemboličnih dogodkov (VTE) po kirurških posegih v trebušni votlini pri odraslih, pri katerih obstaja povečano tveganje za pojav trombemboličnih zapletov, npr. bolniki po resekciji tumorja v trebušni votlini (glejte poglavje 5.1).
Prevention of Venous Thromboembolic Events (VTE) in medical patients who are at high risk for thromboembolic complications due to restricted mobility during acute illness
Preprečevanje venskih trombemboličnih dogodkov (VTE) pri internističnih bolnikih, pri katerih obstaja velika nevarnost trombemboličnih zapletov zaradi omejene gibljivosti (imobilizacije) med akutno fazo bolezni
Prevention of Venous Thromboembolic Events (VTE) in patients undergoing hip fracture surgery treated for up to 24 days following an initial prophylaxis of 1 week
Preprečevanje venskih trombemboličnih dogodkov (VTE) pri bolnikih po operaciji zloma kolka, ki so se po začetni enotedenski profilaksi zdravili še 24 dni
Prevention of VTE (VTEp): elective hip or knee replacement surgery
Preprečevanje venskih trombemboličnih dogodkov: načrtovana kirurška zamenjava kolka ali kolena (VTEp)
Prevention of VTE - Dosing adjustment of fondaparinux is not necessary.
Preprečevanje VTE - Prilagajanje odmerka ni potrebno.
Prevention of VTE - Fondaparinux is known to be mainly excreted by the kidney.
Preprečevanje VTE - Znano je, da se fondaparinuks izloča predvsem preko ledvic.
Prevention of VTE - Fondaparinux should not be used in patients with creatinine clearance <20 ml/min (see section 4.3).
Preprečevanje VTE - Fondaparinuksa se ne sme uporabljati pri bolnikih, ki imajo kreatininski očistek < 20 ml/min (glejte poglavje 4.3).
Prevention of VTE - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment.
Preprečevanje VTE - Pri bolnikih z blago ali zmerno okvaro jeter odmerka ni treba prilagajati.
Prevention of VTE - Patients with body weight <50 kg are at increased risk of bleeding.
Preprečevanje VTE - Bolniki s telesno maso < 50 kg imajo povečano tveganje za krvavitev.
Prevention of VTE - Patients with body weight <50 kg are at increased risk of bleeding.
Preprečevanje VTE – Bolniki s telesno maso < 50 kg imajo povečano tveganje za krvavitev.
Prevention of VTE and Treatment of UA/NSTEMI and STEMI - Dosing adjustment of fondaparinux is not necessary.
Preprečevanje VTE in zdravljenje UA/NSTEMI in STEMI - Prilagajanje odmerka ni potrebno.
Prevention of VTE and Treatment of UA/NSTEMI and STEMI - No dosing adjustment is necessary in patients with either mild or moderate hepatic impairment.
Preprečevanje VTE in zdravljenje UA/NSTEMI in STEMI - Pri bolnikih z blago ali zmerno okvaro jeter odmerka ni treba prilagajati.
Prevention of VTE and Treatment of UA/NSTEMI and STEMI - Patients with body weight <50 kg are at increased risk of bleeding.
Preprečevanje VTE in zdravljenje UA/NSTEMI in STEMI - Bolniki s telesno maso < 50 kg imajo povečano tveganje za krvavitev.
Prevention of VTE: elective hip or knee replacement surgery
Preprečevanje VTE: načrtovana kirurška zamenjava kolka ali kolena
Previcox 227 mg chewable tablets Firocoxib
Previcox 227 mg žvečljive tablete Firokiksib
Previcox 57 mg chewable tablets Firocoxib
Previcox 57 mg žvečljive tablete Firokiksib
Previcox contains the active substance firocoxib, which belongs to a class of medicines having anti- inflammatory action.
Zdravilo Previcox vsebuje zdravilno učinkovino firokoksib, ki spada v razred zdravil s protivnetnimi učinki.
Previcox tablets are supplied in blisters (transparent PVC /aluminium foil) or in 30 ml or 100 ml high density polyethylene bottles (with polypropylene closure).
Previcox tablete so v pretisnih omotih (prozorni PVC/aluminijasta folija) – ali 30 ml in 100 ml polietilenskih plastičnih vsebnikih (s polipropilenskim pokrovom).
Previous ADI*
Prejšnji ADI
Previous anti-diabetic medication was discontinued for 12 weeks prior to baseline measurements.
Predhodna zdravila proti sladkorni bolezni so bila ukinjena 12 tednov pred opravljenimi izhodiščnimi preiskavami.
Previous bilateral salpingo-oophorectomy, or hysterectomy.
Predhodna bilateralna salpingo-ooforektomija ali histerektomija.
previous history of
tudi ne povezane s
Previous history of muscular toxicity with a statin or a fibrate
Mišična toksičnost pri uporabi statina ali fibrata v anamnezi
Previous history of muscular toxicity with a statin or a fibrate
Toksičnost za mišičje pri uporabi statina ali fibrata v anamnezi
previous history of symptomatic arrhythmias concurrent therapy with any of the following drugs, which may interact and result in potentially life-threatening undesirable effects (see sections 4.4, 4.5 and 4.8):
anamnezo simptomatske aritmije, sočasno terapijo s katerim od naslednjih zdravil, ki lahko medsebojno delujejo in povzročijo potencialno življenjsko ogrožajoče neželene učinke (glejte poglavji 4.4, 4.5 in 4,8):
previous history of symptomatic arrhythmias concurrent therapy with any of the following drugs, which may interact and result in potentially life-threatening undesirable effects (see sections 4.4, 4.5 and 4.8):
anamnezo simptomatske aritmije, sočasno terapijo s katerim od naslednjih zdravil, ki lahko medsebojno delujejo in povzročijo potencialno življenjsko ogrožajoče neželene učinke, (glejte poglavji 4.4, 4.5 in 4.8):
Previous Partial Responders***
Predhodno delno odzivni